373 related articles for article (PubMed ID: 28153010)
1. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma.
GongSun X; Zhao Y; Jiang B; Xin Z; Shi M; Song L; Qin Q; Wang Q; Liu X
J Cell Physiol; 2019 Jul; 234(7):12019-12028. PubMed ID: 30523643
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
4. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
5. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
6. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
7. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
[TBL] [Abstract][Full Text] [Related]
8. Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Al-Khayal K; Abdulla M; Al-Obeed O; Al Kattan W; Zubaidi A; Vaali-Mohammed MA; Alsheikh A; Ahmad R
Oncol Rep; 2016 Mar; 35(3):1281-6. PubMed ID: 26675982
[TBL] [Abstract][Full Text] [Related]
9. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
Liu B; Pan S; Xiao Y; Liu Q; Xu J; Jia L
J Exp Clin Cancer Res; 2018 Dec; 37(1):316. PubMed ID: 30547804
[TBL] [Abstract][Full Text] [Related]
10. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
11. ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFα.
Sinha S; Ghildiyal R; Mehta VS; Sen E
Cell Death Dis; 2013 May; 4(5):e615. PubMed ID: 23640457
[TBL] [Abstract][Full Text] [Related]
12. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
Jain S; Washington A; Leaf RK; Bhargava P; Clark RA; Kupper TS; Stroopinsky D; Pyzer A; Cole L; Nahas M; Apel A; Rosenblatt J; Arnason J; Kufe D; Avigan D
Mol Cancer Ther; 2017 Oct; 16(10):2304-2314. PubMed ID: 28729399
[TBL] [Abstract][Full Text] [Related]
13. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.
Hasegawa M; Sinha RK; Kumar M; Alam M; Yin L; Raina D; Kharbanda A; Panchamoorthy G; Gupta D; Singh H; Kharbanda S; Kufe D
Clin Cancer Res; 2015 May; 21(10):2338-47. PubMed ID: 25712682
[TBL] [Abstract][Full Text] [Related]
14. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
15. Coptisine-induced apoptosis in human colon cancer cells (HCT-116) is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway.
Han B; Jiang P; Li Z; Yu Y; Huang T; Ye X; Li X
Phytomedicine; 2018 Sep; 48():152-160. PubMed ID: 30195873
[TBL] [Abstract][Full Text] [Related]
16. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
Ma T; Zhang Y; Zhang C; Luo JG; Kong LY
Biochem Pharmacol; 2017 Nov; 143():90-106. PubMed ID: 28774732
[TBL] [Abstract][Full Text] [Related]
18. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.
Wanka C; Steinbach JP; Rieger J
J Biol Chem; 2012 Sep; 287(40):33436-46. PubMed ID: 22887998
[TBL] [Abstract][Full Text] [Related]
19. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling.
Wang K; Huang W; Sang X; Wu X; Shan Q; Tang D; Xu X; Cao G
Phytomedicine; 2020 Mar; 68():153191. PubMed ID: 32135457
[TBL] [Abstract][Full Text] [Related]
20. β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation.
Park KR; Nam D; Yun HM; Lee SG; Jang HJ; Sethi G; Cho SK; Ahn KS
Cancer Lett; 2011 Dec; 312(2):178-88. PubMed ID: 21924548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
